The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF Aβ Peptides in Healthy Subjects: Results from a Rising Single Dose Study

March 9, 2012

Speaker: Mark S. Forman, MD, PhD

Friday, April 27, 2012

1:00 p.m. – 1:15 p.m.

Biographical Information:

Mark Forman is Director of Clinical Research in the Department of Clinical Pharmacology at Merck.  Dr. Forman joined Merck in 2007 where his work focuses on early clinical drug development, primarily in the therapeutic areas of Neurology and Psychiatry.  Dr. Forman received his B.S. in Molecular Biophysics and Biochemistry at Yale University, Ph.D. in Immunology from Rockefeller University, and M.D. at Duke University.  He completed residency training in Anatomic Pathology and fellowship training in Neuropathology at the University of Pennsylvania.  He also completed postdoctoral training in the Center for Neurodegenerative Disease Research at the University of Pennsylvania with Drs. Virginia Lee and John Trojanowski.  Prior to joining Merck, Dr. Forman was an Assistant Professor of Pathology at University of Pennsylvania where his research focused on the pathogenesis of neurodegenerative disease, including Alzheimer's disease, Parkinson's disease and Frontotemporal Dementia.  At the University of Pennsylvania, Dr. Forman was Director of the brain bank in the Center for Neurodegenerative Disease Research and Director of the Neuropathology Core of the Alzheimer's Disease Center. 

 email to a friend  |   print